In a recently published retrospective review of Canadian NSCLC patients with the three most common EGFR driver mutations, the ex20ins cohort had 18 patients, of which 72.2% received systemic therapy; the median OS from the initiation of first-line systemic therapy was 10.5 months [26]. Here, EGFR is linked to non-small cell lung carcinoma.